28 February 2024
28 February 2024
Viking’s GLP-1/GIP receptor agonist met primary and secondary endpoints in the Phase II obesity trial.
Whilst Minerva deals with clinical deficiencies, eyes turn to Karuna’s PDUFA date and other key Phase III readouts later this year.
The company will activate 105 new clinical sites across Spain, France, Germany, Italy, and Poland.
Overall recurrence-free survival is the trial’s primary endpoint.
Assessing the IMNN-001 combination regimen’s potential in reducing MRD is the primary endpoint of the trial.
An ovarian cancer patient with ARID1A gene faults responded well, with tumour reduction continuing for over five years.
The early feasibility study aims to enrol 30 participants to evaluate the balloon device.
Cabenuva’s formulation consists of two separate agents: Vocabria and Rekambys.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
